The Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report

Ramadhan, Mochamad Iskandarsyah Agung; Sitanaya, Shierly Novitawati; Hakim, Ariadri Hafian Wulandaru; Ramli, Yetty

doi:10.3390/medicina59030453

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the nephrotoxicity and cardiotoxicity associated with iron chelators, their usage is currently limited to experimental settings [ 179 ]. Furthermore, there is a need for additional research to explore the clinical applicability and long-term outcomes of iron chelation therapy in TBI patients [ 180 ].…”

Section: Reviewmentioning

confidence: 99%

Broadening horizons: ferroptosis as a new target for traumatic brain injury

Wei,

Yu,

Zhao

et al. 2024

Burns &Amp; Trauma

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide, with ~50 million people experiencing TBI each year. Ferroptosis, a form of regulated cell death triggered by iron ion-catalyzed and reactive oxygen species-induced lipid peroxidation, has been identified as a potential contributor to traumatic central nervous system conditions, suggesting its involvement in the pathogenesis of TBI. Alterations in iron metabolism play a crucial role in secondary injury following TBI. This study aimed to explore the role of ferroptosis in TBI, focusing on iron metabolism disorders, lipid metabolism disorders and the regulatory axis of system Xc−/glutathione/glutathione peroxidase 4 in TBI. Additionally, we examined the involvement of ferroptosis in the chronic TBI stage. Based on these findings, we discuss potential therapeutic interventions targeting ferroptosis after TBI. In conclusion, this review provides novel insights into the pathology of TBI and proposes potential therapeutic targets.

show abstract

Section: Reviewmentioning

confidence: 99%

Broadening horizons: ferroptosis as a new target for traumatic brain injury

Wei,

Yu,

Zhao

et al. 2024

Burns &Amp; Trauma

View full text Add to dashboard Cite

show abstract

“…The "mass effect," inflammatory responses, and iron-induced secondary damage (Jiang et al, 2020) necessitate medical interventions targeting secondary injury. These include anti-inflammatory agents (Ironside et al, 2021) and iron chelating agents (Ramadhan et al, 2023). Surgical evacuation of the hematoma represents a therapeutic approach for cerebral hemorrhage.…”

Section: Introductionmentioning

confidence: 99%

Effects of Dl-3-n-butylphthalide on neurological function, hemodynamics and Hcy concentration in cerebral hemorrhage: a systematic review and meta-analysis

Ma,

Guo,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundDl-3-n-Butylphthalide (NBP) has emerged as a potential therapeutic agent for cerebral hemorrhage, despite not being included in current guideline recommendations. Investigating the underlying physiological and pathological mechanisms of Dl-3-n-Butylphthalide in cerebral hemorrhage treatment remains a critical area of research.ObjectiveThis review aims to evaluate the efficacy of Dl-3-n-Butylphthalide in cerebral hemorrhage treatment and elucidate its potential biological mechanisms, thereby providing evidence to support treatment optimization.MethodsA comprehensive search of seven electronic databases (PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, VIP, and Wanfang Database) was conducted for studies published up to September 2023. Screening and data extraction were performed by a team of researchers. The Cochrane collaboration tool was utilized for risk bias assessment, and Revman 5.3 along with Stata 17.0 were employed for statistical analysis.OutcomesWe searched 254 literature, and 19 were included in this meta-analysis. The results showed that Dl-3-n-Butylphthalide improved the clinical efficacy rate (RR = 1.25, 95% CI 1.19–1.31; p = 0.00), quality of life (MD = 13.93, 95% CI: 11.88–15.98; p = 0.000), increased cerebral blood flow and velocity, reduced cerebral edema volume, Hcy concentration, and did not have obvious adverse reactions (RR = 0.68, 95% CI: 0.39–1.18; p = 0.10).ConclusionThis meta-analysis is the first to demonstrate the potential of Dl-3-n-Butylphthalide in treating cerebral hemorrhage. It suggests that Dl-3-n-Butylphthalide may alleviate clinical symptoms by modulating neurological function and improving hemodynamics. Our findings provide robust evidence for incorporating Dl-3-n-Butylphthalide into cerebral hemorrhage treatment strategies, potentially guiding future clinical practice and research.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ display_record.php?RecordID=355114, Identifier CRD42022355114.

show abstract

“…This trial suggested safety and hinted at therapeutic efficacy in humans, which is promising for the diffusion of this potential therapy from "bench to bedside." (16,19,20).…”

mentioning

confidence: 99%

Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes

Shirani,

Meshkini,

Hashemi

et al. 2024

Preprint

View full text Add to dashboard Cite

1. Background and Objective: Spontaneous Intracranial Hemorrhage (ICH) is a catastrophic medical condition associated with significant morbidity and mortality. As the accumulation of unbound iron following ICH contributes to secondary brain injury, deferoxamine, an approved chelation drug, has become the center of attention. At the same time, its therapeutic remains a matter of dispute. This double-blinded Randomized Controlled Trial (RCT) aims to investigate the therapeutic potential of deferoxamine in neurological and radiological aspects. 2. Methods and Materials: The study enrolled 42 participants diagnosed with spontaneous ICH and confirmed by CT scan, randomly assigning them to either the deferoxamine treatment group or the placebo control group. While the control group received the routine treatment plus a placebo, the treatment group received routine treatment conjugated with 7.5 mg/kg of deferoxamine per hour intravenously over the first three days. The study compared hematoma and edema volume, GCS score, and mortality rates between the two groups. Our study employed rigorous randomization and blinding procedures to ensure unbiased results. 3. Results: There was a significant (p<0.05) improvement in patients' GCS up until the fourth day, but no significant difference was noted afterward. In addition, the volume of both edema and hematoma was significantly lower in the intervention group, as well as the length of stay, intubation requirement, and mortality. 4. Discussion: Deferoxamine administration can, at least in a short timeframe, improve neurological and radiological parameters.

show abstract

The Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report

Cited by 3 publications

References 30 publications

Broadening horizons: ferroptosis as a new target for traumatic brain injury

Broadening horizons: ferroptosis as a new target for traumatic brain injury

Effects of Dl-3-n-butylphthalide on neurological function, hemodynamics and Hcy concentration in cerebral hemorrhage: a systematic review and meta-analysis

Deferoxamine in Spontaneous Intracranial Hemorrhage: A Pilot Study on Neurological and Radiological Outcomes

Contact Info

Product

Resources

About